Literature DB >> 8680901

Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases.

A Propst1, T Propst, M Herold, W Vogel, G Judmaier.   

Abstract

BACKGROUND: Immunoregulatory properties of cytokines may mediate disordered inflammatory events in inflammatory bowel diseases (IBDs). On the basis of data obtained in experimental colitis, the hypothesis has been advanced that in IBD the balance between interleukin-1 (IL-1) and the naturally occurring IL-1 receptor antagonist (IL-1ra) might influence disease expression.
OBJECTIVE: We studied the profiles of IL-1ra and acute phase proteins produced by activated macrophages to determine whether the level of IL-1ra in peripheral blood is a marker of disease activity in IBD and a possible differential diagnostic marker. PATIENTS AND METHODS: Levels of IL-1ra, serum neopterin, urinary neopterin, alpha 1-glycoprotein and C-reactive protein (CRP) were measured in 80 patients with ulcerative colitis, Crohn's disease or infectious colitis.
RESULTS: Levels of IL-1ra were markedly increased in patients with active ulcerative colitis or active Crohn's disease compared with those in patients with infectious colitis. Patients with active Crohn's disease had significantly higher serum IL-1ra levels than patients with active ulcerative colitis. Moreover, a positive correlation was found between levels of C-reactive protein, alpha 1-glycoprotein, and serum neopterin and the level of IL-1ra in active Crohn's disease but not in active ulcerative colitis, strongly suggesting that the pathogenesis of the two conditions differs.
CONCLUSION: Levels of IL-1ra in the peripheral blood of patients with IBD are of clinical relevance, representing a potent marker of disease activity and a possible differential diagnostic marker.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8680901     DOI: 10.1097/00042737-199511000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

Review 1.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

2.  Urine proteomics for profiling of human disease using high accuracy mass spectrometry.

Authors:  Alex Kentsis; Flavio Monigatti; Kevin Dorff; Fabien Campagne; Richard Bachur; Hanno Steen
Journal:  Proteomics Clin Appl       Date:  2009-09-01       Impact factor: 3.494

3.  Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis.

Authors:  Kyoya Sakimura; Toshihide Omori; Etsuro Iwashita; Takeshi Yoshida; Yoshikazu Tsuzuki; Kenji Fujimori; Fumio Konishi; Yukio Yoshida; Hiroo Anzai; Hiromichi Suzuki; Souichi Sugawara; Yuji Takeda; Katsuya Hiraishi; Abbi R Saniabadi; Tatsuo Ide; Soichiro Miura; Shinichi Ota
Journal:  Dig Dis Sci       Date:  2006-08-12       Impact factor: 3.199

4.  Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

Authors:  J L Fahey; N Aziz; J Spritzler; S Plaeger; P Nishanian; J L Lathey; J Seigel; A L Landay; R Kilarui; J L Schmitz; C White; D W Wara; R Akridge; J Cutili; S D Douglas; J Reuben; W T Shearer; M Nokta; R Polland; R Schooley; D Asthana; Y Mizrachi; M Waxdal
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

5.  Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic.

Authors:  J C Cabrera-Abreu; P Davies; Z Matek; M S Murphy
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

6.  Elevated serum values of procollagen III peptide (PIIIP) in patients with ulcerative colitis who will develop pseudopolyps.

Authors:  Zarko Babic; Vjekoslav Jagić; Zvonko Petrović; Ante Bilić; Kapetanović Dinko; Goranka Kubat; Rosana Troskot; Mira Vukelić
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

7.  Oral fluids as an alternative to serum for measurement of markers of immune activation.

Authors:  P Nishanian; N Aziz; J Chung; R Detels; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

8.  Discovery and validation of urine markers of acute pediatric appendicitis using high-accuracy mass spectrometry.

Authors:  Alex Kentsis; Yin Yin Lin; Kyle Kurek; Monica Calicchio; Yan Yan Wang; Flavio Monigatti; Fabien Campagne; Richard Lee; Bruce Horwitz; Hanno Steen; Richard Bachur
Journal:  Ann Emerg Med       Date:  2009-06-25       Impact factor: 5.721

9.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.